CSM Advisors LLC Acquires Shares of 386,534 Sanofi $SNY

Key Points

• CSM Advisors LLC bought a new stake of 386,534 shares in Sanofi during Q3, valued at about $18.24 million according to its Form 13F filing.
• Sanofi currently trades near $43.60 with a market cap of $106.34 billion and a P/E of 12.11, and its 12‑month range is $43.34–$59.17.
• Analysts have a consensus rating of Hold with a $62.67 price target, and several brokers (including Guggenheim and Barclays) have recently downgraded the stock.

CSM Advisors LLC bought a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 386,534 shares of the company's stock, valued at approximately $18,244,000.

Other institutional investors have also recently made changes to their positions in the company. Financial Consulate Inc. bought a new position in Sanofi during the 3rd quarter valued at about $26,000. First Horizon Corp bought a new stake in Sanofi in the third quarter worth about $33,000. Salomon & Ludwin LLC lifted its stake in Sanofi by 1,046.3% in the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company's stock worth $39,000 after purchasing an additional 701 shares during the last quarter. Traub Capital Management LLC purchased a new position in shares of Sanofi during the second quarter valued at approximately $51,000. Finally, Mather Group LLC. purchased a new position in shares of Sanofi during the third quarter valued at approximately $59,000. Institutional investors own 14.03% of the company's stock.

Sanofi Price Performance

SNY opened at $43.60 on Friday. Sanofi has a 12-month low of $43.34 and a 12-month high of $59.17. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. The business's fifty day simple moving average is $46.85 and its 200-day simple moving average is $48.22. The company has a market capitalization of $106.34 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 1.13 and a beta of 0.45.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SNY. Weiss Ratings reiterated a "hold (c)" rating on shares of Sanofi in a report on Monday, December 29th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Sanofi in a report on Monday, December 8th. Wall Street Zen downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 21st. Guggenheim lowered Sanofi from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 9th. Finally, Barclays downgraded Sanofi from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $62.67.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.